API & Intermediate

Letrozole is a new generation of highly selective aromatase inhibitor, which is a synthetic benzyltriazole derivative. By inhibiting aromatase, letrozole can reduce the level of estrogen, so as to eliminate the stimulating effect of estrogen on tumor growth. The in vivo activity is 150-250 times stronger than that of the first generation aromatase inhibitor amlumide. Because of its high selectivity, it does not affect the function of glucocorticoid, mineralocorticoid and thyroid. High dose use has no inhibitory effect on the secretion of adrenal corticosteroids, so it has a high therapeutic index. Preclinical studies have shown that letrozole has no potential toxicity, mutagenic and carcinogenic effects on various systems and target organs of the body, and has less toxic and side effects, good tolerance. Compared with other aromatase inhibitors and anti estrogen drugs, letrozole has stronger anti-tumor effect. It is suitable for the treatment of patients with advanced breast cancer who are not effective in the treatment of estrogen and early treatment of breast cancer.

L-2-Aminobutyric acid is a natural amino acid that inhibits neural information transmission in humans and is an important chemical feedstock and pharmaceutical intermediate, which has become an important chiral intermediate for a variety of chiral drugs and is widely used in drug synthesis, for example, l-2-aminobutyric acid is the main production feedstock for the synthesis of the novel antiepileptic drug levetiracetam, Is also a key chiral precursor for the synthesis of the bacteriostatic antitubercular drug ethambutol hydrochloride.

This product is a dopamine D2 receptor antagonist. In clinical treatment, it is used as antidepressant, tranquilizer and digestive aid.

2-Fluoro-5-Formylbenzonitrile is used to prepare heterocyclic compounds as medicinal PARP inhibitors.

Mirabelon tablets, developed by Estelle pharmaceutical company of Japan, were listed in Japan on September 16, 2011 and approved by the US Food and Drug Administration (FDA) on June 28, 2012 for the treatment of adult overactive bladder (OAB). Mirabelon was the first to be used to treat overactive bladder β 3. Adrenoceptor agonists, whose successful marketing fills the gap β There is a blank of adrenoceptor agonists in the treatment of overactive bladder.